CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 618 enrolled
Drug / intervention
Dalteparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00922766
NCT00922766N/ACompleted
CompareCT.gov

Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

Pfizer·observational·Posted Jun 17, 2009·Updated Jan 23, 2012

In Brief

An observational study evaluating Dalteparin for Acute Coronary Syndrome. Completed, enrolled 618 participants across 24 sites.

Detailed Summary

To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without percutaneous corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome
CountriesIndia
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 17, 2009
Enrollment StartMay 1, 2009
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.0 years ago

Interventions

Dalteparindrug

Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).